Recommendations for a paradigm shift in approach to increase the recognition and treatment of sialorrhea in Parkinson's disease

被引:3
|
作者
Bergmans, Bruno [1 ,2 ]
Clark, Veronica [3 ,4 ]
Isaacson, Stuart H. [5 ]
Baumer, Tobias [6 ]
机构
[1] AZ St Jan Brugge Oostende Av, Dept Neurol, Campus Brugge,Ruddershove 10, B-8000 Brugge, Belgium
[2] Ghent Univ Hosp, Dept Neurol, B-9000 Ghent, Belgium
[3] Malta Parkinsons, POB 17,Marsa MTP 1001, Marsa MTP1001, Malta
[4] Private Practice, London, England
[5] Parkinsons Dis & Movement Disorders Ctr Boca Raton, 951 NW 13th St,Bldg 5-E, Boca Raton, FL 33486 USA
[6] Univ Lubeck, Inst Syst Motor Sci, CBBM Bldg 66,Ratzeburger Allee 160, D-23562 Lubeck, Germany
关键词
Sialorrhea; Parkinson's disease; Botulinum toxin; BoNT; Recommendation; CAREGIVER BURDEN; ORAL-HEALTH; PREVALENCE; SALIVA; IMPACT;
D O I
10.1016/j.prdoa.2023.100223
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Sialorrhea, or drooling, is defined as excessive saliva accumulation and unwanted loss of saliva from the mouth or over the tongue and into the pharynx. It constitutes one of the most frequent and bothersome complaints of patients with Parkinson's disease (PD), affecting up to 84% of them. Sialorrhea is a distressing and challenging condition that may result in social isolation, embarrassment, depression, skin infections, poor oral health, and aspiration pneumonia. To better understand the burden of sialorrhea on patients with PD, Parkinson's Europe carried out a worldwide patient survey which showed that sialorrhea remains an underrecognized and undertreated issue in patients with PD. This is especially problematic because effective therapeutic options are available. This article presents the results of the Parkinson's Europe Sialorrhea Survey, which were considered by a multidisciplinary panel of experts to provide recommendations for improving the awareness, diagnosis, management, and treatment of sialorrhea in patients with PD. A shift in the treatment paradigm for sialorrhea in patients with PD is emerging. It is essential to better educate patients, family members, caregivers, and healthcare professionals about sialorrhea; to engage all those involved to actively discuss sialorrhea and measure its impact on quality of life; and to recognize the role of botulinum toxin and speech and language therapy as first-line therapies.
引用
收藏
页数:8
相关论文
共 50 条
  • [1] Recommendations for a paradigm shift in approach to increase the recognition and treatment of sialorrhea in Parkinson's disease (Vol 9, 100223, 2023)
    Bergmans, Bruno
    Clark, Veronica
    Isaacson, Stuart H.
    Baeumer, Tobias
    CLINICAL PARKINSONISM & RELATED DISORDERS, 2024, 10
  • [2] Recommendations to Tackle Under-recognition and Under-treatment of Sialorrhea in Parkinson's Disease: Is it Time for a Paradigm Shift?
    Bergmans, B.
    Clark, V.
    Isaacson, S.
    Baumer, T.
    MOVEMENT DISORDERS, 2023, 38 : S181 - S181
  • [3] Recommendations to tackle under-recognition and under-treatment of sialorrhea in Parkinson's disease: Is it time for a paradigm shift?
    Bergmans, Bruno
    Clark, Veronica
    Isaacson, Stuart
    Baeumer, Tobias
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2023, 455
  • [4] Recommendations to Tackle Underrecognition and Undertreatment of Sialorrhea in Parkinson's Disease: Is It Time for a Paradigm Shift?
    Bergmans, Bruno
    Clark, Veronica
    Isaacson, Stuart H.
    Baeumer, Tobias
    TOXICON, 2024, 237 : 9 - 10
  • [5] Glycopyrroniumbromide for the treatment of sialorrhea in Parkinson's disease
    Arbouw, M. E. L.
    Movig, K. L. L.
    Koopmann, M.
    Poels, P. J. E.
    Guchelaar, H. -J.
    Egberts, T. C. G.
    Neef, C.
    van Vugt, J. P. P.
    MOVEMENT DISORDERS, 2009, 24 : S255 - S255
  • [6] Glycopyrroniumbromide for the treatment of sialorrhea in parkinson's disease
    Arbouw, Maurits E. L.
    Movig, Kris L. L.
    Koopmann, Miriam
    Poels, Petra J. E.
    Guchelaar, Henk-Jan
    Egberts, Toine C. G.
    Neef, Cees
    van Vugt, Jeroen P. P.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 68 (05) : 782 - 782
  • [7] Dihydroergotoxine mesylate for the treatment of sialorrhea in Parkinson's disease
    Cheng, Yong-Qing
    Ge, Nian-Nian
    Zhu, Hong-Hong
    Sha, Zhi-Tao
    Jiang, Teng
    Zhang, Ying-Dong
    Tian, You-Yong
    PARKINSONISM & RELATED DISORDERS, 2019, 58 : 70 - 73
  • [8] Rimabotulinumtoxin B for the treatment of sialorrhea in Parkinson's disease
    Alvarez, M. V.
    Grogan, P. M.
    Alvarez, M.
    MOVEMENT DISORDERS, 2013, 28 : S92 - S93
  • [9] Sialorrhea in Parkinson's Disease
    Isaacson, Jonathan
    Patel, Sanskruti
    Torres-Yaghi, Yasar
    Pagan, Fernando
    TOXINS, 2020, 12 (11)
  • [10] The treatment of sialorrhea with botulinum toxin (BTXA) in Parkinson's disease
    Panisset, M.
    Spevack, L.
    Wiseman, M.
    MOVEMENT DISORDERS, 2007, 22 : S83 - S83